SCHEMBL7067100

SCHEMBL7067100

Cc1cc(C)c(S(=O)(=O)NC2(C(=O)O)CCCCC2)c(C)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.49
HTT P42858 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
MMP1 P03956 1/20 0.47
MMP2 P08253 1/20 0.47
MMP9 P14780 1/20 0.47
MMP8 P22894 1/20 0.47
MMP13 P45452 1/20 0.47
FABP4 P15090 1/20 0.43
F2 P00734 1/20 0.41
PRSS1 P07477 1/20 0.41
PRSS2 P07478 1/20 0.41
PRSS3 P35030 1/20 0.41
PYGL P06737 5/20 0.41
CYP2C9 P11712 1/20 0.41
MAPT P10636 1/20 0.40
RAB9A P51151 1/20 0.40
POLB P06746 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7065804 0.78 SMN1; SMN2 (0.60) USP2HTTSMN1; SMN2CA1CA2
SCHEMBL7064210 0.75 USP2 (0.48) USP2HTTSMN1; SMN2CA1CA2
SCHEMBL14676611 0.74 USP2 (0.70) USP2HTTSMN1; SMN2MMP1MMP13
SCHEMBL14675901 0.73 HTT (0.46) USP2HTTSMN1; SMN2CA1CA2
SCHEMBL14676658 0.73 USP2 (0.59) USP2HTTSMN1; SMN2FABP4GAA
SCHEMBL7064077 0.73 ALDH1A1 (0.46) USP2HTTSMN1; SMN2MAPTPOLB
SCHEMBL5675304 0.72 USP2 (0.60) USP2HTTSMN1; SMN2CA1CA2
SCHEMBL14676247 0.72 USP2 (0.56) USP2HTTSMN1; SMN2FABP4GAA
SCHEMBL7066331 0.71 USP2 (0.56) USP2HTTSMN1; SMN2MMP1MMP13
Benzene SCHEMBL6382232 0.71 USP2 (0.44) USP2HTTSMN1; SMN2MMP1MMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030130251-A1 Amino lactam sulfonamides as inhibitors of A-beta protein production THOMPSON LORIN A (US) 2003-07-10 US disclosed
US-6503901-B1 Alzheimer*s disease and Down*s syndrome treatment BRISTOL MYERS SQUIBB PHARMA COMPANY 2003-01-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030130251-A1 Amino lactam sulfonamides as inhibitors of A-beta protein production APP, APH1A, BACE1 USP2 1089/4885HTT 1221/4885SMN1; SMN2 324/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.